LYPLA1 and diabetes mellitus: Decreased endothelial APT1 enzyme activity in diabetic patients suggests its involvement in diabetes progression; APT1 deficiency has been shown by both in vivo and in vitro experiments to lead to abnormal insulin secretion and β-cell failure, and defective palmitoylation of Scamp1 effectively reverses this pathological phenotype.